Related Experiment Video
Updated: Aug 10, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review
F Peinemann1, E C van Dalen2, F Berthold1
1Pediatric Oncology, University Children's Hospital, Cologne.
Klinische Padiatrie
|April 5, 2016
Summary
Rapid COJEC induction chemotherapy for high-risk neuroblastoma did not significantly improve complete response or reduce mortality compared to standard chemotherapy. Current evidence is insufficient to determine its effects, with standard treatment showing better early toxicity profiles.
Area of Science:
- Pediatric Oncology
- Pharmacological Research
- Clinical Trial Analysis
Background:
- High-risk neuroblastoma presents a poor prognosis for affected patients.
- Rapid COJEC induction chemotherapy involves administering standard doses over a shorter period.
- This intensified chemotherapy regimen is theorized to potentially overcome drug resistance and improve outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of rapid COJEC induction chemotherapy versus standard induction chemotherapy in high-risk neuroblastoma patients.
- To compare complete response rates and treatment-related mortality between the two chemotherapy regimens.
Main Methods:
- A systematic review of randomized controlled trials was conducted.
- Databases searched included CENTRAL, MEDLINE, and EMBASE up to November 11, 2014.
- One randomized controlled trial involving 262 participants (130 rapid COJEC, 132 standard OPEC/COJEC) was identified and analyzed.
Main Results:
- No statistically significant difference was observed in complete response rates (RR 0.99, P=0.94) or treatment-related mortality (RR 1.21, P=0.77) between rapid COJEC and standard chemotherapy.
- Standard chemotherapy was associated with a statistically significant reduction in early toxicities, including febrile neutropenia, septicemia, and renal toxicity.
- The single identified trial provided limited data for definitive conclusions.
Conclusions:
- Rapid COJEC induction chemotherapy did not demonstrate statistically significant advantages over standard induction chemotherapy in terms of complete response or treatment-related mortality for high-risk neuroblastoma.
- Standard chemotherapy showed a better early toxicity profile.
- Further research is needed to clarify the role and effects of rapid COJEC induction chemotherapy in this patient population.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...